# A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Source: https://onco.cc/trials/nct05128825/  
OnCo record `nct05128825` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Azenosertib in ovarian cancer, run by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, now recruiting.

## Summary

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer is a phase 2 interventional study registered as NCT05128825 by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, with 310 participants planned, started 2022-02-17 and due to reach its primary completion in 2026-12-01. Interventions recorded: azenosertib. Conditions listed: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05128825
- Phase: 2
- Setting: A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)
- Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Enrolled: 310

## Sources

- ClinicalTrials.gov NCT05128825: https://clinicaltrials.gov/study/NCT05128825

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Azenosertib](https://onco.cc/drugs/azenosertib/)

---
JSON: https://onco.cc/api/v1/entities/nct05128825.json